Morgan Stanley reiterates WuXi AppTec as its top pick in China Healthcare

Overview

This is a Morgan Stanley investor presentation on China Healthcare and WuXi AppTec. The report argues that leading indicators in the CDMO ecosystem have improved significantly since 2026, with WuXi AppTec positioned at the core of the current upcycle, benefiting from growing outsourced demand for innovative small molecules, TIDES, GLP-1, and new treatment paradigms.

Core views

Core views include: first, small molecules accounted for more than 70% of US FDA approvals over the past ten years, supporting durable demand; second, global capacity for innovative small molecules and TIDES remains tight, with order backlogs and improving book-to-bill at Chinese CDMOs; third, GLP-1 drug sales and next-generation pipelines remain strong, driving demand for peptide manufacturing capacity; fourth, WuXi AppTec has relatively high participation in new modalities such as oligonucleotides, PROTACs, molecular glues, CRISPR, cell and gene therapies, viral vectors, and ADCs.

Analysis framework

The report analyzes WuXi AppTec from six angles: industry demand, order metrics, capacity constraints, pipeline, business-segment model, and valuation. Key methods include tracking CDMO book-to-bill, comparing order win rates and market share, assessing GLP-1 and TIDES capacity expansion, and estimating target price through DCF.

Methodology notes

• Valuation methodsdiscounted cash flow

  DCF valuation

  The A-share target price is based on a DCF approach with key assumptions of WACC at 10% and terminal growth rate at 4%; the H-share target price is derived from the A-share target price, assuming an HKD:RMB exchange rate of 1.10.

• industry_indicatorbook-to-bill ratio

  book-to-bill

  The report defines book-to-bill as backlog growth in the latest period divided by trailing 12-month revenue. A ratio above 1.0 indicates demand exceeds supply, and companies with stronger manufacturing profiles and above this threshold receive a premium.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi AppTec Co Ltd (2359.HK; 603259.SS)

  Core coverage name and top-pick recommendation

  Strengths

  89 commercialization contracts, 94 phase III projects, relatively high small-molecule order-win rates, leading coverage in TIDES and GLP-1 projects, and deep participation in multiple new treatment modalities.

  Weaknesses

  High US revenue exposure with persistent geopolitical discount; some growth assumptions depend on end-market sales, outsourcing rates, and capacity utilization.

  Comparison

  The report states its forward one-year A/H-share P/E is about 17x and 19x, below most slower-growth peer CDMOs with smaller project portfolios.

  Risks

  End-market sales falling short of expectations, loss of exclusivity on major commercialization contracts, VC/PE funding volatility, and shifts in US-China relations.

• WuXi XDC Cayman Inc.

  Related new-modality asset

  Strengths

  WuXi AppTec holds an 18.5% stake, and the report links it to participation in ADC and other new treatment modalities.

  Weaknesses

  The report does not provide a standalone financial model or target price.

  Comparison

  It is cited as part of WuXi AppTec's new-modality positioning.

  Risks

  Competition in the ADC field, funding conditions, and regulatory changes could affect related value.

Key data

• Commercialization contracts89WuXi AppTec has 89 commercialization contracts.
• Phase III projects94WuXi AppTec has 94 phase III projects.
• Small molecule FDA approval share>70%Small-molecule drugs accounted for more than 70% of US FDA approvals in the past ten years.
• WuXi AppTec historical order-win rateabout 28%The seven-year average order-win rate is about 28%, and the report also notes a gap between about 30% order-win rate and about 10% current market share.
• GLP-1 project coverage24 projects, about 24% global shareAs of end-2025, WuXi AppTec supports 24 GLP-1 projects, with 99 globally.
• TIDES revenue guidance2026 YoY growth of 40%WuXi AppTec reiterates full-year TIDES revenue guidance of 40% year-over-year growth.
• Peptide output58 tons in 2025, 36.5 tons in 2024Peptide output increased by about 60% year-on-year in 2025.
• Oligonucleotide market sizeUS$31.5bn by 2030, 2024-2030 CAGR >30%Oligonucleotide therapeutics are described as the fastest-growing sub-segment within TIDES.
• Earnings forecast adjustment2026-2030e raised by 4-6%The revision is driven by higher revenue and profit assumptions in Chemistry, Testing, and Biology.
• Target priceA-share Rmb153.0; H-share HK$168.0The report reiterates the target price.

Impact & implications

If the report's thesis holds, WuXi AppTec could benefit simultaneously from rising outsourcing ratios at global pharma companies, shortages in innovative small-molecule capacity, scaling commercialization of GLP-1, and deeper penetration of new treatment modalities. The report also argues that despite more than 30% performance year-to-date in A/H shares, valuation remains below some peer CDMOs with slower growth and smaller project portfolios.

Risks

• End-market sales for major commercialization contracts not meeting expectations, for example if exclusivity is lost.
• Volatility in VC/PE financing could affect innovative drug R&D and outsourcing demand.
• US-China relations and geopolitical risks may continue to create valuation discounts.
• If utilization does not rise, margin expansion may fall short of expectations.

What to watch

• Whether WuXi AppTec's book-to-bill remains above 1.0.
• The pace of small-molecule FDA approvals and the number of new commercialization contracts.
• Progress of next-generation GLP-1 launches, prescription sales, and CDMO signing activity.
• TIDES revenue growth rate, peptide solid-phase synthesis capacity expansion, and utilization rates.
• US-China relations, US revenue exposure, and potential regulatory changes.